Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Rivia launches AI-powered clinical trial data review module, with Scancell as early adopter
(1h)
Valo and Montai become one as the Flagship AI-based biotechs tie the knot
(4h)
Could we see 10 Chinese Big Pharmas within a decade? Some CEOs think so
(5h)
Amgen builds Sjögren’s case with detailed phase 3 data ahead of Novartis showdown
(6h)
Capricor, NextCure reveal recent layoffs as they gear up for approval decision, merger
(9h)
Abbott nabs FDA approval, CE Mark for implantable cardioverter-defibrillator lead
(13h)
Beam’s sickle cell therapy results tee up potential Casgevy, Lyfgenia showdown
(23h)
Start Center for Cancer Research opens first early-phase clinical trial site in Italy
(1d)
PepGen’s stock doubles as midphase muscle dystrophy data wow analysts
(1d)
AstraZeneca buys partner Omniose for bacterial vaccine technology
(1d)
Mirum scores again in hepatitis D phase 3, setting the stage for brelovitug’s FDA run
(1d)
‘Flying blind’: Why experts fear Treasury’s China biotech investment crackdown will backfire
(1d)
Novocure denied FDA approval for Optune Mya cancer device after efficacy concerns
(1d)
AbCellera becomes latest biotech to abandon dream of developing OX40 drug
(1d)
Coherus shrinks headcount 30% to narrow focus of cancer combo
(1d)
Deerfield Management Partners with Amazon’s AWS for AI drive in life sciences
(1d)
Merck’s MASH hopeful efinopegdutide wins in mid-stage study
(2d)
‘Cancer hasn't seen this molecule before’: Onchilles’ injection shows potential for solid tumors
(2d)
J&J-backed Delix drums up $100M series C for non-hallucinatory psychedelic for depression
(2d)
AHA: Boehringer aims for 2027 survodutide submission after obesity drug passes cardio test
(2d)
BioPharma Dive
Drug price hikes in Germany could push US costs higher, study says
(3h)
AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warning
(5h)
PepGen soars on promising early data for muscular dystrophy drug
(21h)
Beam’s base editing therapy for sickle cell hits goal in pivotal trial
(1d)
London biotech Oyster harvests $60M for tau-targeting brain drugs
(1d)
BIO unveils plan for US to remain biotech’s ‘global leader’
(1d)
Bayer wins FDA nod for a new kind of blood thinner
(1d)
Vir hepatitis D drug succeeds in first pivotal study
(2d)
Argenx to buy peptide platform in potentially billion-dollar deal
(2d)
Ramaswamy’s biotech baggage haunted his political run
(2d)
State incentives for commercial-stage life sciences companies
(2d)
Translating Phase II success into Phase III readiness takes more than scale
(2d)
Making the ‘impossible’ executable in life sciences construction
(2d)
Novartis reveals cancer cases possibly linked to gene therapy Zolgensma
(5d)
Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down
(5d)
This week in charts: 3 drug launches Wall Street is watching
(5d)
Medicare will cut billions from 340B, expand site-neutral payments in 2027
(6d)
At ASH, drugmakers to showcase early data for three-pronged cancer therapies
(6d)
Revolution’s Rasonque off to best cancer drug launch ‘in history’
(6d)
T-Therapeutics reloads with a $133M megaround for bispecifics
(6d)
Endpoints News
Flagship merges two startups; J&J scores a bipolar mania success
(3h)
Beeline reveals Phase 2 lupus data from old Bristol Myers drug
(5h)
UK science minister calls for more life sciences investment
(5h)
VectorY bags $83.5M for antibody gene therapies in neurodegenerative diseases
(6h)
Merck KGaA lands FDA nod for joint tumor drug it licensed from Abbisko
(7h)
Despite midterm losses, RFK Jr. is bullish on MAHA's future
(21h)
Mirum plans FDA submission for hepatitis D treatment as competition brews
(1d)
Oura to buy AI care startup Counsel Health for $625M
(1d)
Democrats ramp up oversight of MFN deals after midterm wins
(1d)
Beam says base-edited sickle cell therapy succeeds in Phase 1/2 study
(1d)
PepGen's oligo succeeds in Phase 2; Ionis' and ImmunityBio's stocks sag
(1d)
Employers vs. consumers: Who stands to disrupt healthcare?
(1d)
White House sticks with Overton, works senators for votes
(1d)
OpenAI's head of health talks helping patients take action
(1d)
London startup raises $60M for degraders aimed at Alzheimer’s protein tau
(1d)
Bayer wins FDA approval for stroke prevention drug Sunharbo
(1d)
How early efforts to build autonomous clinical AI tools are approaching regulation
(2d)
Trump’s drug pricing deals force tough choices on launches
(2d)
FDA orders GLP-1 drugmakers to warn of rare eye disease
(2d)
US government removes WuXi AppTec from Chinese military list
(2d)
BioSpace
FDA warns Chinese providers of compounding APIs over record-request refusals
(3h)
PepGen shares almost double as DM1 oligonucleotide achieves ‘best in class’ splicing
(4h)
Capricor parts ways with 10% of staff as FDA decision on DMD cell therapy nears
(4h)
Capricor ramps up manufacturing spend ahead of FDA decision for DMD therapy
(4h)
Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November
(8h)
China has a clear shot to 2030 goals, though economic, cultural barriers remain
(13h)
Without US action on China’s innovation blitz, biotech leaders see a Rust Belt future
(14h)
FDA's rare disease framework faces its first real test in Capricor’s DMD drug
(1d)
Coherus cuts 30% of staffers, Gyre makes post-acquisition layoffs
(1d)
BIO pitches US plan to beat China in biotech ‘space race’
(1d)
Beam preps FDA run for industry-first base-edited therapy after pivotal sickle cell success
(1d)
Bayer wins first-in-class FDA nod for blood thinner, setting stage for BMS-J&J rival
(1d)
Delix raises $100M to advance at-home psychedelic without hallucinatory effects
(1d)
Delix raises $100M to advance at-home psychedelic without hallucinogenic effects
(1d)
Altimmune gears up for FDA meeting on pivotal Phase 3 trial in alcohol use disorder
(1d)
BioSpace 2027 Best Places to Work shines light on most admired employers
(1d)
FDA orders class-wide GLP-1 label update to include potential risk for rare eye disease
(2d)
Boehringer, Zealand’s obesity drug doesn’t elevate heart risk in key late-stage test
(2d)
Lilly to seek second sleep apnea approval after Foundayo reduces disease severity in Phase 3
(2d)
Vir's hepatitis delta combo tamps down virus as Gilead showdown looms
(2d)
STAT News
What MAHA’s support for Russell Brand tells us about the movement
(1h)
BMI alternative would flip obesity diagnosis for millions, study finds
(3h)
Why this former ER doc thinks giving AI less information is sometimes better
(4h)
Senate health committee schedules vote on FDA commissioner nominee Overton
(4h)
We’re reading about Dems eyeing Trump MFN deals, fewer drug launches in Europe, and more
(5h)
The U.S. may soon lose measles elimination status
(6h)
MDCalc launches a ‘rumble strip’ for doctors using generative AI tools
(10h)
Doctors on Kennedy’s influential preventive care panel have major conflicts of interest, filings reveal
(10h)
A new tactic in the war over out-of-network bills: Health care providers are suing employers
(10h)
Low-income parents can’t afford to take chances with nutritious food their picky eaters might reject
(10h)
Democrats take new step toward investigating Trump’s drug pricing deals
(19h)
Wyden, Sanders hand-in-hand on ‘Medicare for All’ initiative
(23h)
Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drug
(1d)
Men’s use of chatbots for therapy, and earnings season highlights
(1d)
Oura to acquire Counsel Health for $625 million, a big bet on AI care
(1d)
GLP-1s are given an FDA warning for rare eye condition risk
(1d)
We’re reading about an approval for novel drug for strokes, a warning for GLP-1 drugs, and more
(1d)
Dutch antitrust regulators probe Biogen over test for its MS drug
(1d)
Pharma is a ‘mixed bag’ when providing drug access to low- and middle-income countries, analysis finds
(1d)
Why this year’s flu season could be hitting teens and young adults hard
(1d)
BioPharma Trend
The Biobank Bet: Why AI’s Next Frontier Is Stored Human Biology — A Conversation with Maccabi’s Michal Tzuchman-Katz
(1d)
The Biobank Bet: Why AI’s Next Frontier Is Stored Human Biology — A Conversation with Maccabi’s Michal Zucman-Katz
(2d)
The $1.8 Billion Bet That More Data Will Enable Progress in Virtual Cells
(1w)
The Virtual Cell Tracker: Who’s Building Them, What Works, Where the Money Goes
(1w)
Anthropic Files for IPO: S-1 Shows 9 of the 10 Largest Pharma Companies in the Fortune 500 Are Paying Customers
(2w)
Benchling’s Science Foundries put teams of AI agents in charge of whole R&D workflows
(4w)
When Agents Run Computations: Schrödinger’s Robert Abel On Where The Human Still Decides
(1mo)
WhiteLab Genomics Raises $26M to Scale AI-designed Delivery Systems for Cell and Gene Therapies
(1mo)
The $2.7B Question: How Do We Know If Isomorphic's AI Works?
(1mo)
Biotech IPOs Roar Back, With Nvidia-Backed Iambic Next in Line
(1mo)
AI Drug Discovery Startups Raise $526 Million in Two Days
(1mo)
Big Pharma Is Betting On LLMs and Agents. What Would Count As Success?
(1mo)
Could Anthropic Disrupt the Techbio Companies Built for Pharma/Biotech?
(1mo)
Is “Rescuing Failed Drugs with AI” a Category Now?
(1mo)
Is the Future of AI Drug Discovery Hybrid?
(1mo)
The Bigger Point Beyond Insilico's Aging Research Milestone
(2mo)
The Measurement Challenge in Longevity: Can Aging Biomarkers and Clocks Close the Gap?
(2mo)
What the New AI Model Releases by Anthropic and OpenAI Change for Life Sciences
(2mo)
Into the Dark: Finding Novel Drug Targets Within the Depths of Our Proteome
(2mo)
Beyond the Code: How DNA Nanotechnology is Moving from Molecular Origami to Programmable Biotech Platforms
(2mo)
Drug Channels
The State of Employer Pharmacy Benefits in 2026: When Plan Savings Come From Higher Patient Costs
(1d)
BlinkRx Insights: Clarifying the Mystery around “DTP”
(5d)
Disintegration: Adam’s Four Takeaways from the CVS Health Breakup
(6d)
Drug Channels Outlook 2027: Adam’s Final Webinar
(1w)
Biopharma’s AI Fork in the Road
(1w)
"How Do I Know I'm Not Just Giving Money Away?" The Question Every Market Access Leader Is Asking
(2w)
Drug Channels News Roundup, October 2026: Part D’s Hidden Cost Sharing Gap, 340B’s $244 Billion Footprint, The Net Price Rebate Model, Cigna’s Wholesale Push, and Four Ways to Bag a Drug
(2w)
Copay + GTN Revenue Protection = Better Together
(3w)
Alternative PBM Satisfaction Declined in 2026, Shrinking the Advantage Over the Big Three PBMs
(3w)
Informa's Trade and Channel Strategies
(3w)
10 Crucial Trends Facing U.S. Drug Wholesalers in 2026 and Beyond
(4w)
NOW AVAILABLE: DCI’s New 2026-27 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors
(4w)
Transparency is No Longer a Compliance Issue
(1mo)
The IRA Fixed One Medicare Part D Distortion—But Patients Now Face New Tradeoffs (rerun)
(1mo)
2025 Gross-to-Net Realities at Eight Top Drugmakers: The Net Pricing Drug Channel Emerges (rerun)
(1mo)
Pharmacist Salaries and Employment in 2025: Retail Declines, Hospital Gains (rerun)
(1mo)
Informa’s PBM Contracting Summit
(1mo)
Patient Support Strategy by Lifecycle Stage: Launch, Growth, Maturity, and Loss of Exclusivity
(1mo)
Drug Channels News Roundup, September 2026: The 340B Margin Squeeze, Economics of Cutting List Price, Patient Adherence from Copay Cards, Negative Part D Premiums, and Drug Channel Dating Profiles
(1mo)
Why GoodRx Is Built for the AI-Driven Patient Journey
(1mo)
European Biotechnology Magazine
VectorY secures €74.5M to advance ALS gene therapy trial
(5h)
Austria builds life sciences momentum
(5h)
SRTD raises €31.5M seed round to develop cell-selective RNA therapies
(1d)
Swiss VC Redalpine closes eighth fund at $250 million
(1d)
Boehringer-Zealand obesity drug clears cardiovascular safety hurdle, but tolerability concerns remain
(1d)
Oyster Therapeutics raises $60M to bring Alzheimer’s tau degrader to clinic
(1d)
Novo, Novartis drugs cut heart-risk markers but not cardiovascular events
(1d)
Windward targets $204M IPO; Valneva’s Shigella vaccine meets Phase 2 endpoint; Ethris’ nasal mRNA lowers viral load
(1d)
Neobe raises $6.8M to break tumor barriers with bacteria
(1d)
Immunocore doubles up on T-cell engagers in eye cancer
(2d)
argenx buys macrocycle partner Unnatural Products for up to $1.15 billion
(2d)
CDMO: How to find a reliable partner
(3d)
When genetic medicine enters the inner ear
(3d)
Turn bioprocess data into timely, transferable process control
(5d)
Spinal muscular atrophy: Tumors reported following Novartis gene therapy
(5d)
Oculis taps Roche veteran after setback; ARTHEx brings in Azafaros’ CMO; CRISPR recruits Orna’s former CTO
(5d)
Dutch biotech Anaheim launches with €40M to develop pseudogout treatment
(5d)
Boehringer secures six Chinese cancer programs in deal worth up to $7B
(6d)
BioNTech: BMS becomes a revenue mainstay — but the pipeline still has to deliver
(6d)
Bayer closes the gap with Boehringer in China’s lung cancer race
(6d)
Drug Hunter
DNA-Encoded Libraries Expand the Reach of Hit Discovery
(4h)
GSK3882347
(1d)
Thinking Outside of the Taxonomic Box: Non-Traditional In Vivo Species in Drug Discovery
(2d)
Lenacapavir, a First-in-Class HIV Capsid Inhibitor for the Treatment and Prevention of HIV-1 Infection
(2d)
Chronic CRFR2 Agonism for Muscle-Sparing Weight Loss
(5d)
RG6182
(6d)
A Deep Dive into INN Proposed List 135 Part 2 (M–Z)
(1w)
A Deep Dive into INN Proposed List 135 Part 1 (A–L)
(1w)
Two Fluorines, One Carbon, Many Possibilities
(1w)
September 2026 Patent Gazette
(2w)
September 2026
(2w)
pamiparib
(2w)
Will Lowering Lp(a) Levels Reduce Cardiovascular Events?
(2w)
Leveraging Platform Innovation to Tackle Tough Targets
(2w)
PF-07976016
(2w)
CNS Cheat Sheet
(3w)
ibrutinib
(3w)
camlipixant
(3w)
zilurgisertib
(3w)
The Sulfoximine Paradox: Understanding the Unique Physicochemical Properties of Secondary Sulfonamide Bioisosteres
(3w)
Labiotech.EU
Preclinical Pulse: The research catching our eye in November 2026
(1d)
Zooming out from ovaries: how has renaming PMOS changed lives?
(5d)
How to turn a BIO-Europe meeting into a lasting partnership
(5d)
From gene editing to RNA therapies: The biotech trends to look out for at AHA Scientific Sessions 2026
(1w)
The biggest biotech funding rounds in October 2026
(1w)
Top biotech deals in October 2026
(1w)
Why global expansion is changing the shape of the ATMP supply chain
(1w)
Teva’s pipeline in 2027: Can it sustain its transformation?
(1w)
ESMO 2026: readouts and highlights at the oncology summit
(2w)
Genprex bets on a one-time gene therapy for diabetes (Part 3 of 3)
(2w)
New idiopathic pulmonary fibrosis drugs on the way
(2w)
TROP2 ADCs: The race to capture the next oncology opportunity
(2w)
13 of the best biotech incubators hatching startups in Europe
(2w)
The stranded asset problem in microbial custom manufacturing
(2w)
Novavax’s new strategy: Betting its future on partnerships
(2w)
Beyond dilation: six biotechs advancing pulmonary hypertension therapies
(3w)
GLP-1 muscle loss: the next battleground in obesity treatment (Part 2 of 3)
(3w)
Oncology biotech news: key moves to watch in October 2026
(3w)
Shifting the standard: myopia companies to look out for
(3w)
Novo’s pipeline in 2026: A new plan to reach $23 billion in sales by 2035
(3w)
Bio IT World
Biosecurity Is Too Important to Be Left Unregulated
(13h)
NCOA7 Emerges as Drug Target Linking Pulmonary Hypertension to Brain Inflammation
(1d)
Fresenius WuXi Biologics Partner, Pfizer Deploys Edison's AI Scientist, Ultima, Illumina Win Singapore National Sequencing Award
(4d)
Gxp Compliance Support Is Coming To The Public Cloud. That’s Good For Life Sciences
(6d)
Quantifying the Average Human Genome
(1w)
Regulatory Affairs Is the Connective Tissue Pharma’s AI Strategy Is Missing
(2w)
Follow the Money: OMass Raises Series C, Pathos AI Drug Development, Owkin Alums Launch Rivercell
(2w)
ParkourSC Acquires Quartic, PacBio Partners with Verily, CAS Data Arrives in Microsoft Copilot
(2w)
Innovating at Speed in an Underrated Drug-Making Process
(3w)
Inside the ‘Public Library of Blueprints’: How the ASAP Discovery Consortium Turned Open Science Into an Antiviral Pipeline
(3w)
New Pipeline Reveals RNA Fusions Formed During Inflammation, Opens New Frontier in Biology
(3w)
From Hard Drives to Self-Service: How ASU and Starfish Storage Unlocked 25 Years of Indigenous Health Data
(4w)
Eric Schadt on Truly Precise Medicine and AI in Pharma and Healthcare
(4w)
2027 Innovative Practices Awards Call for Entries
(4w)
Is AI The Key To Earlier Detection Of Pharmaceutical Safety Risks?
(1mo)
MIT Microscope Captures Whole-Brain Voltage Activity at Millisecond Speed, Opening New Doors for Neurotech and Drug Discovery
(1mo)
Record-Setting Brain Organoid Holds Vast Medical Potential
(1mo)
Follow the Money: Gene Therapy, Pediatric Brain Cancer CAR T, Thyroid Eye Disease
(1mo)
Sanofi Hands 20 Mature Medicines to Cheplapharm, NVIDIA Backs Verily, Roche Inks $1B Bispecifics Deal with Dualitas
(1mo)
AI-Powered Diagnostic Advances Organ Transplant Surveillance
(1mo)
GEN News
How Breast Cancer Chemotherapy May Impact Biological Aging and Loss of Healthy Life Years
(1d)
From Farm Waste to Medical Nanoparticles
(1d)
Hybrid Model Captures Lactate Run-Away and Back-Metabolism
(1d)
Extracellular Vesicle Product Developer Creates Potency Assay
(1d)
Automation a Path to Lower Cell Therapy Costs
(1d)
Argenx Expands Immunology Capabilities with Up-to-$1.15B UNP Acquisition
(1d)
Illumina Offers Early Access to Duplex Sequencing for MRD, Tumor Evolution Research
(1d)
How Cancer-Associated Gene Triggers Cell Division Without Unpacking the Genome
(2d)
Childhood Cancers May Not Always Need Extra Mutations to Spread, Study Suggests
(2d)
New AI Models Are Turbo-Charging Protein Design
(2d)
Therapeutic Immune Manipulation
(2d)
Formulation Development Roundup
(2d)
StockWatch: Nurix Nosedives as Sanofi Halts Phase I Immunology Candidate
(2d)
The Aging Proteome: Clocks, Cohorts, and Clinical Trials
(4d)
Novartis Confirms Nine Cases of Tumors in Children Treated with Gene Therapy Zolgensma
(5d)
ER-Negative Breast Cancer Risk Linked with Blood Levels of Two PFAS Forever Chemicals
(5d)
Why Glycosylation Control Is No Longer a Secondary Concern in the Development of Complex Biologics
(5d)
Where DNA Copying Fails Can Decide How Cancer Cells Respond to PARP Inhibitors
(5d)
Boehringer Ingelheim Inks Up-to-$7.4B+ Cancer Drug Collaboration with Sino Biopharmaceutical
(6d)
Bird Flu Vaccine Developed Using AI Outperforms Current Stockpiled Vaccines in Preclinical Tests
(6d)
Cure Today
Living With BRCA and Ovarian Cancer: Leanne Citrone's Story
(1h)
Patient Advocacy Advice From a Colon Cancer Survivor
(3h)
Medicare Part D 2027: What a $2,400 Cap Means for Cancer Drugs
(5h)
Inside the Clinic: How One Hematologist Approaches a Rare Leukemia
(22h)
The Day I Tapped My Son Out of Basic Training
(23h)
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumor
(1d)
Neuroendocrine Tumors: 7 Questions Patients Ask, Answered
(1d)
Why Rituxan Plus Cladribine May Delay Hairy Cell Leukemia Relapse
(1d)
Glioblastoma Patients Can Request Genomic Testing on Their Tumor Tissue
(1d)
Weight Loss With Pancreatic Cancer: Why It Happens and What Helps
(2d)
Rural Lung Cancer: Only 36% of Medicare Patients Had Gene Testing
(2d)
Datroway Slows Brain Metastases in Triple-Negative Breast Cancer
(2d)
Nearly Half of Cancer Survivors Report Recent Alcohol Use
(4d)
Hot Flash Drug Works at Any Point in Breast Cancer Hormone Therapy
(4d)
Glioblastoma Genomic Testing: What Patients Should Ask
(4d)
How Patients With Breast Cancer Can Catch Lymphedema Before Swelling Starts
(5d)
Survivor Guilt After a Double Mastectomy for DCIS Breast Cancer
(5d)
FDA Approves Rybrevant Faspro for Advanced Head and Neck Cancer
(5d)
Enhertu Before Surgery Falls Short in HER2-Low Early Breast Cancer
(5d)
Pancreatic Cancer and Enzyme Pills: Why They Matter at Every Meal
(5d)
Contract Pharma
Valo Health Merges with Montai Therapeutics, Company Will Keep Valo Name
(11m)
Neuvivo Appoints Mike McGrath as CEO
(15m)
Devia Spins Out of Visium to Aid Pharma Companies with GxP Deviations
(1h)
FDA Approves Merck, Darmstadt, Germany’s Pimjetmi for Symptomatic TGCT
(2h)
T-Cypher Bio Expands Oxford Operations with Move to Abingdon Science Park
(3h)
Körber Launches Cloud-Native PAS-X Neo MES for Smaller Pharma Manufacturers
(4h)
QbDVision Appoints Christoph Pistek as VP, Digital CMC Solutions
(4h)
Circio, Solid Biosciences Partner on Next-Generation Cardiac Gene Therapy
(5h)
Novacyt’s Yourgene Wins Australian Approval for DPYD Chemotherapy Toxicity Test
(5h)
ProBio, AbTis Enter License Agreement for Next-Gen ADC Asset Development
(21h)
AGC Biologics, Child’s Cure Genetic Research Partner on mRNA Discovery for Rare Epileptic Disorder
(22h)
ProBioGen Berlin Viral Manufacturing Facility Gets Extended Authorization, Updated GMP Certificate
(1d)
Simtra BioPharma Opens $250M+ Bloomington Building, Expanding Manufacturing Campus
(1d)
PharmaLogic Acquires Lantheus CDMO Unit, Expands U.S. Radiopharma Capacity
(1d)
Azurity Pharmaceuticals Builds Global Growth Around Outsourced Manufacturing
(1d)
MedPharm Lands Manufacturing Deal for First-to-File Generic Topical Drug
(1d)
Evonik Produces First GMP Lipids at Indiana Facility
(1d)
Uncountable Launches Environmental Monitoring Tool for GMP Cleanrooms
(1d)
Quanticate Appoints Praveen Arockiaraj as VP & Head of Clinical Data Management
(1d)
Spruce Bio Spins CAH Program Off into New Subsidiary Adrenyx
(1d)
Pharma Times
Japan approves prefilled syringe for GSK’s shingles vaccine
(1mo)
EpilepsyGTx and Viralgen partner to scale AAV manufacturing for EPY201
(1mo)
Zerion partner files first EU application for Dispersome‑enabled product
(1mo)
Tozorakimab shows broad COPD benefit in new phase 3 data
(1mo)
Study highlights advance in influenza protection for older adults
(2mo)
NICE backs daratumumab quadruplet for transplant‑eligible myeloma
(2mo)
Teitur reports positive early data for Parkinson’s peptide TT‑P34
(2mo)
Amivantamab regimen delivers longest survival in EGFR Ex20ins lung cancer
(2mo)
NICE backs ibrutinib regimen for untreated mantle cell lymphoma
(2mo)
Livdelzi accepted in Scotland for treatment of PBC
(2mo)
Jemperli accepted for priority review by US FDA
(2mo)
Carterra supports AI‑designed protein study with HT-SPR platforms
(2mo)
Erasca secures FDA fast track for eras‑0015 in pancreatic cancer
(2mo)
Avulux gains FDA authorisation for migraine light‑sensitivity lens
(2mo)
Leqembi Iqlik launches in US for early Alzheimer’s
(2mo)
Lundbeck gains EU orphan status for anti‑ACTH antibody
(2mo)
AC Immune reports positive phase 1 data for ACI‑19764
(2mo)
VarmX begins global phase 3 trial of VMX C001
(2mo)
VarmX begins global phase 3 trial for VMX C001
(2mo)
FairJourney Bio unveils tumor‑conditional IL‑12 breakthrough
(2mo)
Medcity News
Follow the Leader: How to Build and Retain Great Clinical Teams
(5h)
Oura’s Buys Counsel for $625M, But Will Payers and Consumers Get on Board?
(19h)
FDA Approves First-in-Class Bayer Drug for Reducing the Risk of Stroke
(22h)
New Campaign Wants AI Applications To Look Beyond Speed
(1d)
The Laboratory Industry’s Next Competitor May Be the Company on Your Patient’s Wrist
(1d)
Startup Supporting Caregivers Raises $3.5M in Seed Funding
(1d)
Digital Health’s GLP-1 Strategy: “You Didn’t Come for the Drug. You Came for Health”
(1d)
Argenx Adds Oral Peptides to Its Immunology Strategy With $550M UNP Acquisition
(1d)
Simulation-Guided Clinical Trials: Is EU Law Ready?
(2d)
Nkarta Autoimmune Disease Cell Therapy’s First Human Data Show Safety, Signs of Efficacy
(2d)
What’s Driving the Consumerization of Healthcare?
(2d)
Missing the Point: Isolation Alone Will Not Build AI Safety
(3d)
Bispecific J&J Drug Wins Speedy FDA Approval for Treating Head & Neck Cancer
(4d)
Experian Health Survey: Providers Struggle Amid Increasing Claim Denials
(5d)
The Big Challenge for AI in Healthcare Comes After Approval
(5d)
Why Physician Leadership Is More Important Than Ever
(5d)
Myths of Customer Discovery
(5d)
Debunked Episode 31: CVS Health Restructure, AI ROI Report Findings, FTC Warning Letters
(5d)
How Can Payers Fit Into the Consumer Health Era?
(5d)
Do We Have a Choice But to Ensure the Success of VBC? Part 1
(5d)
Chemical & Engineering News
Sorry, it’s a scam—what to look out for in your job search
(39m)
Periodic Graphics: Fighting flu: How flu vaccines are made
(3h)
C&EN Chempics Close-Ups, Nov. 11
(6h)
California voters OK $8.4 billion for immunology amid funding questions
(21h)
Business Watch: 3M settles PFAS cases for $7.35 billion, and more
(1d)
ACS Board elects Carolyn Ribes as 2027 chair
(1d)
Green chemistry sector navigates China’s influence
(1d)
Nominations sought for 2027 Crano Memorial Lecture
(1d)
First cohort of ACS-Moore Postdoctoral Bridge Award in Quantum Materials recipients announced
(1d)
No, drug outsourcing firms haven’t abandoned the small molecule
(1d)
Comment: To NOBCChE, community is everything
(1d)
Chemistry in Pictures: Golden tears
(2d)
Mitsui Chemicals will acquire JSR in electronic materials push
(2d)
Purple bacteria transform waste into valuable antioxidant
(2d)
ACS expands public policy fellowships
(2d)
Comment: Creating pathways to success through Project SEED
(2d)
Uncovered: Plastic pyrolysis
(2d)
C&EN Chemwords, Nov. 9
(2d)
‘Journal of Physical Chemistry Letters’ names next editor in chief
(5d)
Using old wind turbine blades to make new ones
(5d)
The Pharma Letter
VectorY raises 74.5 million euros to take TDP-43 ALS therapy through Phase I/II readout
(2h)
Teva targets $6-7 billion innovative medicines revenue by 2030 at first R&D Day
(3h)
Positive new Phase III data for Amgen’s dazodalibep
(4h)
Shionogi enters license agreement with Link for cefiderocol
(5h)
Kesmalea rebrands as Oyster with $60 million, Lilly-backed round for oral tau degrader
(5h)
Kesmalea rebrands as Oyster with $60 million, Lilly-backed round for oral tau degrader
(5h)
Circio and Solid Bio collaborate for genetic heart disease technology
(6h)
China tightens IIT oversight to safeguard CGT data integrity
(7h)
Nuformix proposes acquisition of Biovara
(7h)
J&J’s Caplyta meets endpoints in second Phase III bipolar mania study, supporting planned FDA filing
(7h)
AstraZeneca acquires vaccine start-up Omniose
(7h)
Launches round-up: 11 November 2026
(9h)
How Japan is bringing missing medicines to patients
(9h)
Genentech at 50 and the making of modern biotech
(9h)
Beam lines up year-end FDA filing after sickle cell trial hit
(9h)
FDA approves Merck KGaA’s Pimjetmi for TGCT
(10h)
Revolution Medicines' Anthony Mancini: “We're just getting started” as Rasonque nears EU approval
(1d)
Revolution Medicines' Anthony Mancini: “We're just getting started” as Rasonque nears EU approval
(1d)
Lundbeck raises full-year guidance as 9 month revenue grows
(1d)
Funnel Biosciences secures up to $2.16B ceal with Third Rock
(1d)
Targeted Oncology
Dr Garmezy on JNJ-6143's Novel Mechanism in Advanced Prostate Cancer
(35m)
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
(1h)
Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL
(2h)
Novocure’s Optune Mya Gets FDA Not Approvable Letter
(3h)
In Phase 3, Ponatinib/Blinatumomab Improves EFS in Ph+ ALL
(4h)
Physician and Practice Factors Shape Advanced Cancer Trial Enrollment
(5h)
Significance of the All-Comer PD-L1 CPS Design
(6h)
OrigAMI-5 Design Rationale for First-Line Use
(6h)
Oncologists Discuss Ibrutinib Switching and Fixed-Duration Therapy in CLL
(21h)
Dr Shitara on Selecting First-Line Therapy in HER2+ GEA
(23h)
Garmezy Discusses Unanswered Questions for JNJ-6143 in Prostate Cancer
(1d)
FDA Approves Pimicotinib for Symptomatic Tenosynovial Giant Cell Tumor
(1d)
Silevertinib CNS Activity Supports Planned Phase 3 in EGFR-Mutant NSCLC
(1d)
Denileukin Diftitox Improves QOL in Responding Patients With CTCL
(1d)
Intracranial Activity and Brain Surveillance With ROS1 Inhibitors
(1d)
Communicating Durability and Hope to Patients
(1d)
Home-Based Trastuzumab Self-Administration Reduces Costs and Time Burden
(1d)
The Patients Missing From Breast Cancer Data
(1d)
Comparing Treatment Approaches in Second-Line Metastatic ccRCC
(1d)
Imneskibart Regimens Show Activity in ICI-Refractory Melanoma, NSCLC
(2d)
MedWatch
Trump’s drug pricing policy could delay new medicines in Europe
(5h)
Two boards are plenty for Lundbeck CEO: “It’s about becoming a better CEO”
(6h)
Lundbeck CEO plays down margin pressure from Vyepti’s success
(6h)
Moderna CEO sees personalized cancer vaccine as potential best-seller
(9h)
Lilly to seek FDA approval for Foundayo in sleep apnea after strong Phase 3 data
(9h)
Olympus raises outlook on stronger GI endoscope sales
(1d)
Zealand partner reports positive heart safety results for obesity drug candidate
(1d)
FDA orders eye disease warning on Novo and Eli Lilly obesity drugs
(1d)
Gubra CEO out after just over a year in the job
(1d)
Lundbeck sharply raises 2026 outlook
(1d)
Coloplast leaves room for a large sign-on bonus for its new CEO but won’t disclose the full amount
(1d)
Ambu board seeks sharp increase in executive bonus caps
(2d)
Demant goes on offensive with US veterans: “We aim to steadily expand our position”
(2d)
Trustee to seek disqualification of former Audientes management
(2d)
Sandoz launches Ozempic copy in Brazil
(2d)
Wegovy improves liver markers in MASH patients without obesity
(2d)
Coloplast nominates Lundbeck CEO to its board
(2d)
Novo Nordisk releases real-world data on semaglutide in fatty liver disease
(2d)
Market turmoil threatens Leo Pharma’s planned IPO, Berlingske reports
(2d)
EU clears GN Hearing sale to Amplifon, bringing billion-krone payout closer
(5d)
In The Pipeline
Think Before You Degrade
(22h)
Jon Clardy, 1943-2026
(2d)
Antimicrobial Peptides for Fun (?) and Profit (?)
(6d)
The Morning After the Midterms
(1w)
Taming Photochemistry
(1w)
Chemotherapy Actually Helps Immunotherapy in Cancer
(1w)
Messing Around With the Warburg Effect
(2w)
Lipidation and Its Discontents
(2w)
What Does It Mean to "Know Medicinal Chemistry"?
(2w)
The Merck/Moderna Results
(3w)
Elevenostat: Don't Believe the Label
(3w)
The Case of the Should-Be-Missing Proteins
(3w)
Two Weeks to Go
(3w)
Sulfur, Right There All Along
(3w)
How LLMs Deal With Fraudulent Papers
(4w)
Accelerated Reactions in an Electric Field
(4w)
The 2026 Nobel Prize in Chemistry: Chirality Abounds
(4w)
Time Off
(1mo)
Hold Up a Minute
(1mo)
Now That's An Impurity Story
(1mo)
Pharmaphorum
Obesity needs a new clinical definition, study finds
(5h)
Google Cloud launches Gemini for Healthcare
(6h)
UK's Levicept builds case for osteoarthritis therapy at ACR
(7h)
AZ boosts vaccine capabilities with Omniose buy
(8h)
Merck's rare tumour drug Pimjetmi claims FDA approval
(9h)
Third Rock in $2bn drug-hunting pact with China's Funnel
(1d)
UK's Oyster Tx rebrands and raises $60m for Alzheimer's RD
(1d)
Hims & Hers to offer unapproved peptides to customers
(1d)
FDA orders blindness risk warning to GLP-1 agonist labels
(1d)
Bayer bags FDA green light for stroke drug Sunharbo
(1d)
Amazon puts $100m into global health drive
(2d)
MHRA grants Innovation Passports to three novel drugs
(2d)
argenx agrees Unnatural takeover deal worth up to $1.15bn
(2d)
Moderna to relocate its UK HQ to London's Tribeca
(2d)
Novartis' pelacarsen fail raises questions for other drugs
(2d)
Lilly partners with Hims & Hers on obesity drug sales
(5d)
Inflammation-focused Rezera sets terms for IPO
(5d)
Moderna, Oxford Uni Ebola jabs backed for pivotal testing
(5d)
UK pilots shorter NICE appraisal for new medicines
(5d)
J&J's Rybrevant moves beyond lung cancer with new approval
(5d)
Drug Discovery Weekly
UQ technology opens new front in Alzheimer’s and Parkinson’s
(2w)
Why we need to rethink childhood cancer treatments
(2w)
Q3 UK biotech VC heads for record year thanks to megadeals
(2w)
Measuring what matters: Applying ultrasensitive immunoassays for clinical biomarkers
(2w)
New webinar: Applying ultrasensitive immunoassays for clinical biomarkers
(2w)
Partnership advances AI-driven R&D collaboration
(2w)
The three generations of obesity medicines
(2w)
Webinar: Exploring warm PDX benefits and onsite expertise
(2w)
Beyond the model: Exploring warm PDX benefits and onsite expertise
(2w)
ScionxBio collaborates to develop long-acting xRNA therapeutics
(2w)
Roche licenses Zymeworks’ trispecific T cell engager targeting DLL3
(2w)
TILT reports encouraging data at ESMO
(2w)
New eBook: Next-generation neuroscience drug discovery
(2w)
Next week: DDW’s Drug Discovery Innovators and Investors (DDII) conference
(2w)
UK Budget promises £70m for life sciences and lifts VAT on free medicines
(2w)
Read the Guide: Predict cardiac safety early
(2w)
Next-generation neuroscience drug discovery
(2w)
Webinar: From PK/PD and biomarkers to decision-making
(2w)
Trial data presented at ESMO support cancer microbiome therapy
(2w)
Designing multiomics studies to capture biological response
(2w)
HIT Consultant
WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans
(7h)
TigerConnect Smart Room Suite: Integrating Epic, Cloud Alarm Management, and Bedside AI
(13h)
Oscar Health and HealthEx Leverage TEFCA Individual Access to Bring Medical Records into AI Workflows on Day One
(14h)
How Real-World Data (RWD) Is the Turning Point for Pharma Innovation
(14h)
M&A: Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care
(1d)
Charta Health Raises $55M to Establish Pre-Claim Ground Truth Across Providers and Payers
(1d)
Google Cloud Launches Gemini for Healthcare: Unifying Payer and Provider Workflows Across Epic, Oracle Health, and MCP Connectors
(1d)
Zus Health Secures $33M to Scale AI-Native Health Data Infrastructure Beyond Legacy EHR Silos
(1d)
Ohio State Wexner Medical Center and Microsoft Ink 5-Year Partnership to Co-Develop the Smart Hospital of the Future
(1d)
GoodRx Launches MCP Integration with Google Cloud Gemini for Healthcare: Real-Time Prescription Pricing at the Point of Care
(1d)
Froncort.AI Secures $2.3M from Google.org to Transform Door-to-Door Infectious Disease Screening
(1d)
Medicare Just Changed What It’s Paying For. Most Chronic Care Programs Haven’t Caught Up.
(1d)
AWS Launches $100M Health Impact Initiative to Scale Agentic and Cloud Tech in Underserved Global Care
(2d)
M&A: XRHealth Acquires PursueCare to Bridge Immersive VR Therapy with FDA-Authorized Prescription Digital Therapeutics
(2d)
Reclaiming $44.9B in Hospital Uncompensated Care via Automated Upfront Eligibility
(2d)
CLEAR Launches Epic Toolbox Integrations for EpicCare Link and DEA-Compliant EPCS
(2d)
SEARHC Joins Mayo Clinic Care Network to Bridge Specialist Tele-Informatics Across Southeast Alaska
(2d)
GDIT, IHS, and Oracle Health Deploy PATH EHR as the First Cloud-Native Federal Health System
(2d)
Why Patient Access Is Healthcare’s Highest-Leverage Growth Lever
(2d)
Do Patients Need to Understand AI Before They Can Trust It?
(4d)
Insights: Pink Sheet
Why The EU JCA For AstraZeneca’s Etcamah Took More Than 100 Days
(4h)
Fast Approval, Delayed Start? EU Speeds Modifications To Clear Trial-Blocking Conditions
(4h)
WuXi AppTec Removed From 1260H List, For Now
(13h)
US FDA Reorg Will Help Address ‘Surge’ In Cell, Gene Therapy Facility Inspections
(20h)
Operation TrialBlazer: US FDA’s Expedited IND Pilot Draws 100+ Applications
(20h)
US FDA Seeking Ideas To Avoid Data Use Problems When RWE Included In Application Reviews
(23h)
Senate Committee To Vote On US FDA Commissioner Nominee Before Dem Takeover
(1d)
AstraZeneca’s Potential Blockbuster Baxdrostat Nears EU Verdict After US Win
(1d)
Innovent Awaits EMA Verdict On Sintilimab After EU JCA Collapse And US Rejection
(1d)
US FDA Defines Risk-Based Potency Approach To Cell and Gene Therapy
(1d)
Korea Streamlines Review Of Digital Convergence Combos
(1d)
US FDA Probes Tumor Risk With Novartis’ Zolgensma And Itvisma After Gene Integration Reports
(1d)
GLP-1 Class Warning On Rare Eye Condition Driven By US FDA Meta-Analysis, Sentinel Study
(1d)
EU Risks ‘Completely Screwing Up’ Pharma Sandboxes, Academic Warns
(2d)
Recruitment To Industry Trials Falls For Fifth Year In UK Despite Faster Approvals
(2d)
Ad/Promo: Multiple US FDA Advisory Comment Requests OK, But Know Their Limits
(4d)
CMS Retains ‘Value Of 12’ For One-Time Therapies In Medicare Negotiation Despite Pushback
(4d)
US FDA Biologics Center Joins Hiring Binge, Posts First Net Gain Since Pre-Trump Administration
(5d)
Pink Sheet Podcast: How Will FDA And Rx Industry Navigate Aftermath Of Midterm’s Blue Wave?
(5d)
UK Flexibility On Non-OECD Data Could Widen Trial Opportunities
(5d)
BioXconomy
Optimizing the Affordability Journey: Insights from a Real-World Brand Case Study
(20h)
GoodRx partners with Google Cloud to bring prescription savings into Gemini for healthcare
(3h)
Veristat, Clene use AI to speed up ALS drug application by 80%
(3h)
Build-a-biotech: Transitioning from academia to commercialization
(7h)
Tighter rules with COINS, DOJ-HHS and EHDS
(22h)
Biopharma firms tap new legal and compliance leads
(23h)
Guangzhou Innogen Pharmaceutical Group presents at BIO-Europe 2026
(23h)
Better data use and diversity engagement could boost UK trial participation
(1d)
Life Sciences Pricing & Contracting West
(1d)
State prescription affordability boards miss true patient cost causes
(1d)
CMS finalizes rule on Medicare Drug Price Negotiation Program
(1d)
Behind the bell: AgomAb's playbook for a European biotech IPO
(1d)
Standardization, not customization: A site-CRO perspective on trial quality
(1d)
Survey finds women are willing to join trials, yet rarely invited
(2d)
Argenx buys into macrocyclic peptides with $1.15bn UNP deal
(2d)
Pharma urged to build pricing resilience
(2d)
Small patients, big breakthrough: Using peptides to treat hypoxic brain injuries in preterm babies
(2d)
Medicare Part D premiums, caps climb in 2027 plans
(5d)
Novartis under scrutiny as nine tumor cases reported in Zolgensma SMA patients
(5d)
Indian CDMO Shilpa commits to $50M expansion in peptide manufacturing
(5d)
BioCentury
PepGen’s DM1 readout hints at functional payoff from splicing correction
(19h)
SITC 2026: Dual targeting, precise integration shape in vivo CAR T development
(20h)
FDA approvals on track for record year
(21h)
Boehringer in six-program tie-up with Sino: Deals Report
(1d)
Overton confirmation unlikely, Brenner under consideration as acting FDA commissioner
(1d)
Novartis’ full HORIZON data deepen doubts about Lp(a) as a target
(1d)
Dose-dependent liver fat reductions support CIDEB as a target in MASLD
(1d)
What the U.S. midterms mean for biopharma — a BioCentury podcast
(1d)
Second M&A deal for argenx gives it Unnatural Products’ macrocyclic peptide platform
(1d)
China’s first-in-class deals grow as U.S. investment curbs loom — a BioCentury podcast
(4d)
Post-election pricing outlook: stormy with a chance of compromise
(4d)
Rezera proposes IPO terms amid volatile NASDAQ conditions: Public Equity Report
(4d)
Brinsupri, Rasonque extend biotech's launch momentum
(4d)
SITC 2026: Engineering immune responses inside tumors
(5d)
With $600M fund, Formation Bio puts a financing twist on hub-and-spoke model
(5d)
Alethio: A mutation-agnostic approach to essential thrombocythemia
(5d)
Nisa Leung’s Aulis Capital closes $200M debut fund: Venture Report
(5d)
Innovation Radar: New clues to targeting Alzheimer’s microglia
(6d)
Building biology’s missing datasets to train AI models
(6d)
FDA approves first DNA plasmid immunotherapy; NME tally reaches 47
(6d)
SCRIP
Oyster Therapeutics Raises $60m To Target Alzheimer’s With Protein Degraders
(2h)
Stock Watch: Lilly’s 52-Week High Meets Alnylam’s 52-Week Low
(2h)
Beam Eyes Risto-Cel BLA As Early As Year-End After Positive Sickle Cell Data
(8h)
ACR 2026: Can ImmuneOnco‘s Bispecific Take On Roche’s Gazyva In SLE?
(10h)
Divamics Targeting Differentiation In Application Of AI To Drug Design
(12h)
AASLD 2026: Regeneron, GSK, Merck Look To Bring Competition In MASH
(21h)
Finance Watch: Proximal Ventures Backs AI-Based Life Sciences Solutions With New Fund
(21h)
Q3 Earnings Roundup: Roivant, Ionis, Lundbeck
(22h)
Scientific Questions Remain As Aumseqa Heads For New EU Verdict Just Weeks After Revocation
(1d)
Boehringer Ready To File Survodutide But At What Threat To Obesity Leaders?
(1d)
Rivia Adds AI-Powered Data Checks To Clinical Trial Platform
(1d)
Bayer All Set For Sunharbo Launch As Stroke Drug Seals FDA Okay
(1d)
Pipeline Watch: Three Approvals And Eleven Phase III Readouts
(1d)
Video Interview: The Future of CDMOs: Integrated Development and Complex Modalities
(1d)
ACR 2026: Novartis/Abogen’s mRNA T-Cell Engager Shows Initial Promise In Scleroderma
(1d)
Astellas Employee Imprisoned In China Reportedly Released Next Month
(1d)
Cultivating An iPSC Ecosystem: RACTHERA CEO On Japan Cell Therapy Journey
(1d)
Novartis’s Detailed Pelacarsen Data Leave Little Hope For Other Lp(a)-Lowering Drugs
(1d)
ACR 2026: A Tale Of Three Cell Therapies
(1d)
Argenx Buys Unnatural Products, Gaining Macrocyclic Peptide Discovery Platform
(1d)